Biotech Startups

Portfolio company acquired by Roche.

3 investors

Greenbone Ortho develops orthopedic medical products and constantly pursues clinical innovation and new applications. The company is based in Italy and focuses on advancing orthopedic treatment solutions.

3 investors

Greenitio develops bio-based specialty ingredients that replace petrochemical and microplastic-based materials in cosmetics and personal care, using a patented green chemistry platform to convert natural polymers into biodegradable alternatives. Its materials target functions such as SPF boosting, texture, and stability, and address the EU's upcoming ban on intentionally added microplastics.

3 investors

GreenMark develops non-invasive dental products for dentists, hygienists, and patients that treat tooth sensitivity and support oral health management. Its offerings include a mineral-depositing dental strip for sensitivity relief and a fluorescent rinse for early caries detection.

3 investors

Grit Bio develops nine core technology platforms for cell therapy manufacturing and development, spanning TIL expansion, viral vector production, immunological target discovery, and LNP delivery systems for therapeutic applications.

3 investors

Grolltex manufactures single-layer graphene and graphene-based products using patented CVD and transfer technologies, serving customers in life sciences, biotech, sensing, and electronics. The company operates a U.S.-based foundry offering graphene materials and processing services with a focus on cost-effective, high-throughput production.

3 investors

Gross-Wen Technologies (GWT) develops the patented RAB algae-based system to treat municipal and industrial wastewater, recovering nutrients from the water and recycling the nutrient-rich algae into slow-release fertilizer. The company serves municipal and industrial clients seeking sustainable wastewater treatment.

3 investors

Novartis is a pharmaceutical company that develops and commercializes prescription medicines and therapies across therapeutic areas including oncology, cardiovascular disease, and immunology.

3 investors

HairDAO is a decentralized research network enabling patients and researchers to collaboratively fund and develop new hair loss treatments through community voting and blockchain-based governance.

3 investors

HarborSite develops a targeted gene insertion platform that engineers site-specific recombinase enzymes to integrate therapeutic genes into safe genomic sites. It aims to create one-time, durable treatments for genetic and age-associated diseases.

3 investors

A research-intensive biopharmaceutical company that develops medicines and vaccines. It serves patients and provides health-related information across global communities.

3 investors

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.

3 investors

Hendrix Genetics develops and supplies animal breeding genetics and technology across multiple species including turkeys, laying hens, poultry, swine, salmon, trout, and shrimp to address global food demand. The company operates through a portfolio of 15 genetic brands across more than 25 countries worldwide.

3 investors

HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.

3 investors

Hera Biotech develops diagnostics for women's health, aiming to detect conditions that legacy tools miss. Its platform is presented as AI-enabled and science-based, intended for clinical care settings.

3 investors

Hera Health Solutions is a biotechnology company that develops a proprietary nanotechnology platform to reformulate existing pharmaceutical compounds into more effective and longer-acting therapies. The platform enables rapid optimization of drugs with improved release profiles, reduced toxicity, and scalable manufacturing.

3 investors

HeraSight develops genetic tests for families, including preimplantation embryo screening that uses polygenic risk scores and carrier screening to predict risks for conditions such as Alzheimer's, schizophrenia, cancers, autism, and diabetes. It combines validated polygenic scoring with genetic counseling for prospective parents undergoing IVF.

3 investors

A biotech and AI company that develops tools to reduce the cost of producing animal health medicines. The company serves veterinary and animal health industries.

3 investors

HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis. The company focuses on cancer patients who have experienced treatment resistance through novel drug development approaches.

3 investors

HiFiBiO Therapeutics develops immunotherapies for patients with high unmet medical needs, using its Drug Intelligence Science (DIS) platform that combines single cell technology with AI/ML analytics. The platform supports target discovery, antibody selection, and predictive biomarker identification for drug development.

3 investors

Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones. It applies disease-specific genetic markers to identify patient populations most likely to benefit from its targeted treatments.

3 investors

Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects. Its focus areas include autoimmune and inflammatory diseases, cancer, and other conditions.

3 investors

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

3 investors

Hoofprint Biome develops probiotics and natural enzymes based on microbiome engineering to reduce methane emissions from cattle while improving animal health and feed yield. The company targets livestock and cattle production within sustainable agriculture.

3 investors